EHA 2024 | CPX-351 versus intensive induction chemo in pts with tAML or AML with myelodysplasia-related changes
Dimitrios Kotsos, MD, Erasmus MC, Rotterdam, Netherlands, discusses a study that aimed to compare the efficacy of CPX-351 with a 7+3 intensive chemotherapy regimen (used in a cohort of patients by the HOVON-SAKK study group) in patients aged 60-75 years with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC). The 7+3 regimen resulted in higher complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates. However, the median overall survival (OS) between the regimens was comparable. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
